Hormone Therapy Tied to Less Biological Aging in Postmenopausal Women
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 3, 2024 -- Postmenopausal women who use hormone therapy (HT) are biologically younger than those not receiving HT, according to a study published online Aug. 29 in JAMA Network Open.
Yufan Liu and Chenglong Li, Ph.D., from Peking University in Beijing, evaluated the association between HT use and discrepancies between chronological and biological age in postmenopausal women, as well as the impact of socioeconomic status (SES). The analysis included data from 117,763 postmenopausal women participating in the U.K. Biobank, of whom 40.3 percent ever used HT.
The researchers found that ever use of HT was associated with a smaller biological aging discrepancy versus never use of HT (β, −0.17 years). This effect was more evident in those who started HT at 55 years of age or older (β, −0.32 years) and in those who used HT for four to eight years (β, −0.25 years). Additionally, the association between HT and a smaller aging discrepancy was stronger in women with low SES, with a significant interaction observed for education (higher education: β, −0.08 years; other education: β, −0.23). For the association between HT and all-cause mortality and cause-specific mortality, phenotypic aging discrepancy mediated 12.7 percent of the effect.
"Promoting HT in postmenopausal women could be important for healthy aging," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-04 15:22
Read more
- Study Assesses Risk for 28-Day Hospitalization for Adults With RSV
- Use of Fan, Skin Wetting Reduces Cardiac Strain in Hot, Humid Conditions
- Ketamine ODs Like the One That Killed Matthew Perry Are Rare But Increasing
- Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
- Risk for Schizophrenia Increased With ED Visits Involving Hallucinogen Use
- Delaying Noncardiac Surgery for Several Months After Heart Attack Found to Be Safer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions